Cocrystal Pharma Inc
NASDAQ:COCP
Operating Margin
Cocrystal Pharma Inc
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| US |
|
Cocrystal Pharma Inc
NASDAQ:COCP
|
16.7m USD | N/A | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
757.1B USD |
40%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
3%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
406.8B USD |
26%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
2T DKK |
45%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
207.8B CHF |
33%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
179.9B CHF |
33%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
165.5B GBP |
24%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
211.3B USD |
34%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
183.8B USD |
11%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
144.2B USD |
27%
|
Cocrystal Pharma Inc
Glance View
Cocrystal Pharma, Inc. is a biotechnology company, which engages in the discovery and development of novel antiviral therapeutics. The company is headquartered in Bothell, Washington and currently employs 13 full-time employees. The company went IPO on 2018-03-12. The firm focuses on developing antiviral therapeutics that inhibit the essential viral replication function of RNA viruses causing acute and chronic viral diseases. The firm focuses on treating influenza virus, coronavirus, hepatitis C virus (HCV) and norovirus infections by discovering and developing drug candidates targeting the viral replication process. The firm uses computational methods to screen and design product candidates using cocrystal structural information. Its development pipeline includes CC-31244 and CC-42344. The Company’s CC-31244 is a pan-genotypic inhibitor of NS5B polymerase for the treatment of hepatitis C infection. The Company’s CC-42344 is a PB2 inhibitor for the treatment of influenza A infection. Its pipeline also includes CDI-45205 for the treatment of coronavirus. The company has also developed chemical libraries consisting of non-nucleoside inhibitors, metal-binding inhibitors, and drug-like fragments.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Cocrystal Pharma Inc's most recent financial statements, the company has Operating Margin of 0%.
You don't have any saved screeners yet